Background: Chemotactic factors play an important role in acute rejection. The aims of our study were to examine the expression of serum and urine IP-10 and Fractalkine in the renal transplant recipients and whether IP-10 and Fractalkine can predict the acute kidney allograft rejection. Method: A total of 162 recipients with kidney transplantation (KTx) were selected and divided into acute rejection group (ARG) and stable allograft function (STA). In addition, 96 unrelated healthy volunteers were obtained as healthy controls (HC). The serum and urine samples from recipients were collected at day 0 and the 1st, 3rd, 5th and 7th post-KTx days. Once acute rejection was developed, the samples were collected on anti-rejection treatment day 0 (before treatment was given), 1, 4, 7 and on the end of treatment. All samples were measured in by ELISA. Results: We found that the levels of Fractalkine and IP-10 reached a peak at the 3rd post-KTx days, and those levels in recipients with ARG were significant higher than that in STA (P<0.05). The concentrations of serum and urine Fractalkine and IP-10 were decreased accordingly at the 5th and 7th post-KTx days, and those levels in recipients with ARG were also significant higher than that in STA (P<0.05). The expression of serum and urine IP-10 and Fractalkine in ARG were significantly increased when acute rejection occurs, comparing to STA (P<0.05), and followed a gradual decline levels during anti-rejection therapy. The expression of IP-10 and Fractalkine recovered to normal level after effective treatment for 1 week. Logistic regression predictive model by combining serum IP-10 and Fractalkine separated acute rejection from non-rejection with a sensitivity of 87% and a specificity of 80.6%, and by combining urine IP-10 and Fractalkine separated acute rejection from non-rejection with a sensitivity of 86% and a specificity of 83%. Conclusion: Fractalkine combination Serum and urine IP10and will provide more sufficient specificity and sensitivity for prediction than single-marker.
This work was supported by the National Natural Science Foundation of China (No. 81270829, 81270548, 81102247).
To cite this abstract in AMA style:Jin Z, Tian P, Xue W, Ding C, Zheng J, Duan W, Mao T, Xi M. Serum and Urine IP–10 and Fractalkine Are Effective Biomarkers for Prediction of Early Kidney Transplant Rejection [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/serum-and-urine-ip10-and-fractalkine-are-effective-biomarkers-for-prediction-of-early-kidney-transplant-rejection/. Accessed November 23, 2020.
« Back to 2013 American Transplant Congress